These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 22490758

  • 1. [The efficacy and safety of low-dose rituximab in treatment of primary Sjögren's syndrome with thrombocytopenia].
    Zhou L, Xin XF, Wu HX.
    Zhonghua Nei Ke Za Zhi; 2012 Jan; 51(1):37-41. PubMed ID: 22490758
    [Abstract] [Full Text] [Related]

  • 2. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.
    Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, Candon S, Le Guern V, Aouba A, Sibilia J, Gottenberg JE, Mariette X.
    Ann Rheum Dis; 2007 Mar; 66(3):351-7. PubMed ID: 16950808
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety of Rituximab in Systemic Lupus Erythematosus and Sjögren Syndrome Patients With Refractory Thrombocytopenia: A Retrospective Study of 21 Cases.
    Jiang B, Li T, Guo L, Shen H, Ye S, Chen S.
    J Clin Rheumatol; 2015 Aug; 21(5):244-50. PubMed ID: 26203828
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry.
    Gottenberg JE, Cinquetti G, Larroche C, Combe B, Hachulla E, Meyer O, Pertuiset E, Kaplanski G, Chiche L, Berthelot JM, Gombert B, Goupille P, Marcelli C, Feuillet S, Leone J, Sibilia J, Zarnitsky C, Carli P, Rist S, Gaudin P, Salliot C, Piperno M, Deplas A, Breban M, Lequerre T, Richette P, Ghiringhelli C, Hamidou M, Ravaud P, Mariette X, Club Rhumatismes et Inflammations and the French Society of Rheumatology.
    Ann Rheum Dis; 2013 Jun; 72(6):1026-31. PubMed ID: 23264337
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry.
    Mekinian A, Ravaud P, Hatron PY, Larroche C, Leone J, Gombert B, Hamidou M, Cantagrel A, Marcelli C, Rist S, Breban M, Launay D, Fain O, Gottenberg JE, Mariette X.
    Ann Rheum Dis; 2012 Jan; 71(1):84-7. PubMed ID: 21926185
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.
    Carubbi F, Cipriani P, Marrelli A, Benedetto P, Ruscitti P, Berardicurti O, Pantano I, Liakouli V, Alvaro S, Alunno A, Manzo A, Ciccia F, Gerli R, Triolo G, Giacomelli R.
    Arthritis Res Ther; 2013 Oct 30; 15(5):R172. PubMed ID: 24286296
    [Abstract] [Full Text] [Related]

  • 7. Rituximab in primary Sjögren's syndrome: a ten-year journey.
    Carubbi F, Alunno A, Cipriani P, Bartoloni E, Ciccia F, Triolo G, Gerli R, Giacomelli R.
    Lupus; 2014 Nov 30; 23(13):1337-49. PubMed ID: 25096066
    [Abstract] [Full Text] [Related]

  • 8. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy.
    Hamza N, Bootsma H, Yuvaraj S, Spijkervet FK, Haacke EA, Pollard RP, Visser A, Vissink A, Kallenberg CG, Kroese FG, Bos NA.
    Ann Rheum Dis; 2012 Nov 30; 71(11):1881-7. PubMed ID: 22615459
    [Abstract] [Full Text] [Related]

  • 9. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus--a prospective pilot study.
    Chen H, Zheng W, Su J, Xu D, Wang Q, Leng X, Zhang W, Li M, Tang F, Zhang X, Zeng X, Zhao Y, Zhang F.
    Rheumatology (Oxford); 2011 Sep 30; 50(9):1640-4. PubMed ID: 21571767
    [Abstract] [Full Text] [Related]

  • 10. Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment.
    Delli K, Haacke EA, Kroese FG, Pollard RP, Ihrler S, van der Vegt B, Vissink A, Bootsma H, Spijkervet FK.
    Ann Rheum Dis; 2016 Nov 30; 75(11):1933-1938. PubMed ID: 26757748
    [Abstract] [Full Text] [Related]

  • 11. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
    Meiners PM, Arends S, Brouwer E, Spijkervet FK, Vissink A, Bootsma H.
    Ann Rheum Dis; 2012 Aug 30; 71(8):1297-302. PubMed ID: 22258489
    [Abstract] [Full Text] [Related]

  • 12. The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjögren's syndrome.
    Saraux A.
    Autoimmun Rev; 2010 Jul 30; 9(9):609-14. PubMed ID: 20452466
    [Abstract] [Full Text] [Related]

  • 13. Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren's syndrome.
    Ciccia F, Guggino G, Rizzo A, Alessandro R, Carubbi F, Giardina A, Cipriani P, Ferrante A, Cannizzaro A, Giacomelli R, Triolo G.
    Rheumatology (Oxford); 2014 Jul 30; 53(7):1313-20. PubMed ID: 24602921
    [Abstract] [Full Text] [Related]

  • 14. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
    Jovancevic B, Lindholm C, Pullerits R.
    Lupus; 2013 Jun 30; 22(7):664-74. PubMed ID: 23612795
    [Abstract] [Full Text] [Related]

  • 15. Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy.
    De Vita S, Quartuccio L, Salvin S, Picco L, Scott CA, Rupolo M, Fabris M.
    Clin Exp Rheumatol; 2014 Jun 30; 32(4):490-4. PubMed ID: 24802131
    [Abstract] [Full Text] [Related]

  • 16. Complete remission of protein-losing gastroenteropathy associated with Sjögren's syndrome by B cell-targeted therapy with rituximab.
    Uraoka Y, Tanigawa T, Watanabe K, Machida H, Okazaki H, Yamagami H, Watanabe K, Tominaga K, Watanabe T, Fujiwara Y, Arakawa T.
    Am J Gastroenterol; 2012 Aug 30; 107(8):1266-8. PubMed ID: 22859008
    [No Abstract] [Full Text] [Related]

  • 17. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.
    Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, Vissink A, Kallenberg CG, Bootsma H.
    Arthritis Rheum; 2005 Sep 30; 52(9):2740-50. PubMed ID: 16142737
    [Abstract] [Full Text] [Related]

  • 18. Treatment of primary Sjögren syndrome with rituximab: a randomized trial.
    Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, Le Guern V, Sibilia J, Gottenberg JE, Chiche L, Hachulla E, Hatron PY, Goeb V, Hayem G, Morel J, Zarnitsky C, Dubost JJ, Pers JO, Nowak E, Saraux A.
    Ann Intern Med; 2014 Feb 18; 160(4):233-42. PubMed ID: 24727841
    [Abstract] [Full Text] [Related]

  • 19. First report of improvement of coeliac disease in a patient with Sjögren's syndrome treated with rituximab.
    Nikiphorou E, Hall FC.
    Rheumatology (Oxford); 2014 Oct 18; 53(10):1906-7. PubMed ID: 24729401
    [No Abstract] [Full Text] [Related]

  • 20. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial.
    Moerman RV, Arends S, Meiners PM, Brouwer E, Spijkervet FK, Kroese FG, Vissink A, Bootsma H.
    Ann Rheum Dis; 2014 Feb 18; 73(2):472-4. PubMed ID: 23940214
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.